| Identification | Back Directory | [Name]
L-165,041 | [CAS]
79558-09-1 | [Synonyms]
100877
CS-760
L 1q5041
L-165,041
COMPOUND P
L-165041, >=98%
L165041; L 165041
L-165,041 - CAS 79558-09-1 - Calbiochem
2-[4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]phenoxy]-
4-[3-(4-ACETYL-3-HYDROXY-2-PROPYLPHENOXY)PROPOXY]PHENOXYACETIC ACID
4-[3-(2-PROPYL-3-HYDROXY-4-ACETYL)PHENOXY]PROPYLOXYPHENOXY-ACETIC ACID
2-(4-(3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy)phenoxy)acetic acid
Acetic acid, 2-[4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]phenoxy]- | [Molecular Formula]
C22H26O7 | [MDL Number]
MFCD04974501 | [MOL File]
79558-09-1.mol | [Molecular Weight]
402.44 |
| Chemical Properties | Back Directory | [Melting point ]
127-128 °C(lit.)
| [Boiling point ]
600.8±55.0 °C(Predicted) | [density ]
1.222±0.06 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
DMSO: >10 mg/mL
| [form ]
solid
| [pka]
3.23±0.10(Predicted) | [color ]
off-white
| [Stability:]
Light Sensitive |
| Hazard Information | Back Directory | [Uses]
L-165,041 has been used as a peroxisome proliferator-activated receptor β/δ (PPARβ/δ) ligand to study its influence on PPARβ/δ mediated postnatal myogenesis in C2C12 myoblasts. | [Definition]
ChEBI: 2-[4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]phenoxy]acetic acid is an aromatic ketone. | [General Description]
A cell-permeable phenoxyacetic acid derivative that acts as a potent and selective peroxisome proliferator activator receptor δ (PPARδ) agonist (Ki = 6 nM for hPPARδ and 730 nM for hPPARγ). Potently induces adipocyte differentiation in NIH-PPARδ cells at 500 nM and raises total cholesterol in insulin resistant db/db mice without altering glucose or triglycerides levels. Increases UCP3 (uncoupling protein 3) gene expression in L6 myotubes. Inhibits cytokine-induced expression of VCAM-1 (vascular cell adhesion molecule-1) and the secretion of MCP-1 (monocyte chemotactic protein-1) in EAhy926 cells. | [Biological Activity]
Potent PPAR δ agonist (K i = 6 nM); displays > 100-fold selectivity for both mouse and human PPAR δ ? receptors over other subtypes. In vivo, raises plasma cholesterol levels in insulin-resistant db/db mice and is neuroprotective in models of cerebral infarction and Parkinson's disease. | [Biochem/physiol Actions]
Cell permeable: yes | [in vitro]
l-165041, which is a selective and potent pparδligand, displayed in this specified transactivation system, apart from its highly efficacious pparδ agonist activity, partial and full agonism at, respectively, pparγ2 and pparαsubtypes [1]. | [in vivo]
l-165041 could drastically reduce lipid accumulation in the mouse liver, decreasing total hepatic triglyceride and cholesterol content compared to the vehicle group. gene analysis demonstrated that l-165041 lowered hepatic expression of pparγ, apolipoprotein b, il-1β, and interleukin-6. in contrast, l-165041 increased hepatic expressions of pparδ, lipoprotein lipase, and atp-binding cassette transporter g1 (abcg1) [2]. | [target]
PPARδ | [storage]
Desiccate at RT | [References]
[1] wurch t, junquero d, delhon a, pauwels j. pharmacological analysis of wild-type alpha, gamma and delta subtypes of the human peroxisome proliferator-activated receptor. naunyn schmiedebergs arch pharmacol. 2002 feb;365(2):133-40.
[2] lim hj, park jh, lee s, choi he, lee ks, park hy. ppardelta ligand l-165041 ameliorates western diet-induced hepatic lipid accumulation and inflammation in ldlr-/- mice. eur j pharmacol. 2009 nov 10;622(1-3):45-51. |
|
| Company Name: |
ChemShuttle, Inc.
|
| Tel: |
0510-83588313-802 18800520310; |
| Website: |
https://www.jiehuapharma.com/ |
|